Skip to content
  • Monday, 29 June 2026
  • 9:11 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Pharmaceutical R&D

Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition

Teuku Ryan Jun 29, 2026 0

Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…

Read More
Science News: A Century of Empowering Public Understanding of ScienceResearchers Develop Revolutionary CST-CMFI Ultrafast Imaging Technique to Observe Complex Microscopic Phenomena in Real TimeThis crocodile ran like a greyhound across prehistoric Britain 200 million years agoBreast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveHigh-Dimensional Topological Structures Discovered in Entangled Photons Offer New Framework for Quantum Information StabilityWater-in-Diesel Emulsion Technology Offers Significant Emissions Reduction Potential Without Engine Modification
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sBiogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion AcquisitionThe Evolving Landscape of Retrieval-Augmented Generation: Addressing Production Failures and Exploring Advanced AlternativesMicrobial Allies: Naturally Occurring Soil Bacteria Offer Hope Against the Growing Threat of Saline Agriculture
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jun 29, 2026
Pharmaceutical R&D
Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Teuku Ryan Jun 29, 2026
Data Science & Bioinformatics
The Evolving Landscape of Retrieval-Augmented Generation: Addressing Production Failures and Exploring Advanced Alternatives
Evan Lee Salim Jun 29, 2026
Molecular & Cell Biology
Microbial Allies: Naturally Occurring Soil Bacteria Offer Hope Against the Growing Threat of Saline Agriculture
Angie Faith Jun 29, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ